Osteoporosis is the most common metabolic bone disorder worldwide and is the leading cause of fragility fractures.
It is a systemic skeletal condition marked by decreased bone mass and the deterioration of bone structure, which increases the risk of fractures, especially in the spine, hip, distal forearm, and proximal humerus.
Go deeper with GlobalData
These fractures greatly contribute to morbidity, often necessitating long recovery periods and full-time care for many patients.
Despite its significant impact, osteoporosis often goes unnoticed until a fracture occurs, earning it the label of a ‘silent disease’.
A June 2024 study conducted by Qiu and colleagues and published in Frontiers in Artificial Intelligence has shown the development of a novel deep neural network (DNN) model with an effective algorithm for early diagnosis and intervention of osteoporosis.
See Also:
Osteoporosis typically develops over several years before resulting in a fracture that brings it to medical attention.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMore than two-thirds of vertebral fractures occur without pain, complicating early detection.
Common symptoms include back pain from fractured vertebrae, which can lead to visible deformity or reduced mobility.
The condition can also cause a stooped posture, known as kyphosis, as vertebral fractures cause the spine to collapse and bend forward, further affecting the individual’s physical functionality and quality of life.
The recent study introduces a novel model aimed at improving the diagnosis and treatment of osteoporosis, particularly in the ageing population.
Existing AI models for diagnosing osteoporosis such as logistic regression and support vector machines, often fall short due to their simplistic data analysis and limited accuracy.
These models can struggle with complex medical data and predicting osteoporosis risk accurately.
The new DNN model overcomes these issues by using advanced techniques to analyse large and diverse data sets.
This results in higher accuracy and better identification of at-risk patients, making it a more reliable tool for early diagnosis and treatment, ultimately improving patient care.
The researchers utilised a comprehensive dataset to develop their DNN model, incorporating diverse patient demographics and clinical variables.
By training the model on this extensive dataset, they aimed to create an algorithm capable of accurately predicting osteoporosis risk and identifying patients who would benefit from early intervention.
The methodology emphasised the importance of using a large, varied data set to ensure the model’s robustness across different populations.
This approach underscores the potential of AI in handling complex medical data and providing actionable insights.
In the course of their study, the researchers employed various machine learning techniques to refine the DNN model.
They compared its performance against logistic regression and support vector machines.
In this study, the DNN model outperformed these conventional methods in accuracy, sensitivity, and specificity.
This suggests that the AI-driven model can more reliably identify patients at risk of osteoporosis, potentially leading to earlier diagnosis and better-targeted treatments.
The study’s findings highlight the significant advantages of incorporating AI into osteoporosis care.
The DNN model demonstrated a high level of accuracy in predicting fracture risk and identifying patients who could benefit from preventive measures.
This capability is crucial, as early diagnosis and treatment can significantly reduce the incidence of fractures and improve quality of life for patients.
Moreover, the model’s ability to process and analyse large volumes of data quickly and accurately makes it a valuable tool for healthcare providers.
Together, the development of this DNN model represents a major advancement in the field of osteoporosis diagnosis and treatment.
For pharmaceutical companies, this innovation offers new opportunities for developing targeted therapies and preventive measures.
By leveraging AI technology, the healthcare industry can improve patient outcomes and reduce the burden of osteoporosis.
As this model is further validated and integrated into clinical practice, it has the potential to transform osteoporosis care and enhance the well-being of ageing populations globally.
